Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-2803 vs Vemlidy PK Study in Healthy Adults
NCT04906109Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-2803 in hepatitis B (HBV) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve to the Last Measurable Concentration at 72 hour and Maximum Plasma Concentration at 72 hour. Started Jul 2021; status: completed.
02
Drugs
DA-2803
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04906109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906109.